Search clinical trials for: Sitagliptin-Metformin

Total 2749 results

Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Co-administration of Sitagliptin and Metformin as Individual Tablets (0431A-095)

Type 2 Diabetes
Merck Sharp & Dohme LLC

Completed

A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)

Type 2 Diabetes Mellitus
Merck Sharp & Dohme LLC

Completed

A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)

Type 2 Diabetes
Baylor College of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

A Pilot Study to Assess the Glucose Lowering Effect of Metformin and Sitagliptin in Adolescents With Type 1 Diabetes

Type 1 Diabetes

United States
Merck Sharp & Dohme LLC

Completed

Bioequivalence Study of Sitagliptin/Metformin Combination Tablet (MK0431A-122)

Type 2 Diabetes
AstraZeneca

Completed

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (A)

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets

Healthy

United States
Merck Sharp & Dohme LLC

Completed

Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)

Type 2 Diabetes Mellitus
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Clinical Study of Retagliptin Phosphate Combined With Metformin in the Treatment of Type 2 Diabetes

Type 2 Diabetes

China
Korea University Anam Hospital
AstraZeneca

Unknown

Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes

Diabetes Mellitus, Type II

Korea, Republic of
Shahid Beheshti University of Medical Sciences

Recruiting

Comparing the Effect of Sitagliptin/Metformin and Metformin in PCOS Patients

Polycystic Ovary Syndrome | Infertility | ART

Iran, Islamic Republic of
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

Type 2 Diabetes
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator

Healthy Subjects
Merck Sharp & Dohme LLC

Completed

Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189)

Diabetes Mellitus, Non-Insulin-Dependent
Merck Sharp & Dohme LLC

Completed

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

Type 2 Diabetes Mellitus
Boehringer Ingelheim

Completed

The Effect of Linagliptin (BI 1356) on 24h-glucose Control and Various Biomarkers in Type 2 Diabetic Patients

Diabetes Mellitus, Type 2

Germany
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence of Sitagliptin Phosphate/Metformin Hydrochloride Tablets in Healthy Chinese Subjects

Healthy Subjects

China
Shanghai 10th People's Hospital

Completed

Non-alcoholic Fatty Liver Disease and Its Treatment

NAFLD
Genuine Research Center, Egypt
Eva Pharma

Completed

Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)

Healthy

Egypt
Evidem Consultores SL
Boehringer Ingelheim; Merck Serono International SA; European Commission

Unknown

Prevention of Microvascular Complications in Prediabetes e-PREDICE Study (ePREDICE)

PreDiabetes

Spain
Boehringer Ingelheim

Completed

Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy

Diabetes Mellitus, Type II
University of Pisa
Merck Sharp & Dohme LLC

Completed

Metformin and Sitagliptin in Women With Previous Gestational Diabetes

Pre-diabetes

Italy
AstraZeneca

Completed

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants

Type 2 Diabetes Mellitus

United States
Universidad de Guanajuato
Hospital Regional de Alta Especialidad del Bajio

Unknown

Effect of Low Dose Combination of Linagliptin + Metformin to Prevent Diabetes

Insulin Resistance | Prediabetic State

Mexico
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin in Combination With Metformin in Treatment Naive Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control

Diabetes Mellitus, Type 2

Bangladesh, Belgium, Canada, China, Germany, Guatemala, Hong Kong, India, Lebanon, Mexico, Peru, Philippines, Spain, Taiwan
VIVUS LLC

Completed

A Drug Interaction Study of VI-0521 With Metformin, Sitagliptan and Probenecid in Healthy Subjects.

Obesity

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
AstraZeneca

Completed

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin

United States
AstraZeneca

Completed

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

Type 2 Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Pharmacokinetics of Fixed Dose Combination (FDC) Tablets of Linagliptin /Metformin

Healthy

China
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Evaluate the Food Effect on Pharmacokinetic Profiles and Safety of CKD-379

Type 2 Diabetes Mellitus

Korea, Republic of
Merck Sharp & Dohme LLC

Completed

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus (T2DM)
Boehringer Ingelheim

Completed

Comparison of the Bioavailability of Metformin Between Medium Dose Linagliptin/Metformin Tablets and Medium Dose Glucophage Tablet Given With Linagliptin Tablet

Diabetes Mellitus, Type 2

Canada
LG Life Sciences

Completed

Effects of Gemigliptin Versus Sitagliptin or Glimepiride With Metformin on Glucose Variability(MAGE, Glucose SD) Patients With Type 2 DM(STABLE Study) (STABLE)

Type 2 Diabetes Mellitus

Korea, Republic of
Bio-innova Co., Ltd

Not yet recruiting

Sitagliptin and Metformin Hydrochloride Tablets 50 mg/500 mg Relative to Originator

Healthy Subjects
The Catholic University of Korea
Bayer

Completed

Study to Evaluate the Efficacy of Acarbose,Metformin,Sitagliptin Combination Treatment in DM Patients

Type 2 Diabetes Mellitus

Korea, Republic of
The University of Texas Health Science Center at...

Completed

Mechanisms of Glucose Lowering Effects of Sitagliptin and Metformin Alone and in Combination in Patients With T2DM

Diabetes

United States
AstraZeneca

Completed

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure (MEASURE-HF)

Heart Failure | Type 2 Diabetes Mellitus

United States, Thailand, Korea, Republic of, Russian Federation, Ukraine, Hungary, Bulgaria, Chile, Canada, Romania
Emory University
Merck Sharp & Dohme LLC

Terminated

DPP-4 Inhibition and TZD for DM Prevention (DInT DM)

Prediabetic State

United States
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Diabetes Mellitus

United States
Boehringer Ingelheim

Completed

Relative Bioavailability of Two Different Batches of a Linagliptin / Metformin Combination Tablet in Healthy Volunteers

Healthy

Germany
Services Hospital, Lahore

Completed

Comparison of Hypoglycaemic Regimens During Ramadan Fasting in Type 2 Diabetes

Diabetes, Type 2

Pakistan
Merck Sharp & Dohme LLC

Completed

MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)

Type 2 Diabetes Mellitus
AstraZeneca
Bristol-Myers Squibb

Completed

18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)

Type 2 Diabetes

Mexico, South Africa, Norway, Argentina, Belgium, Denmark, Sweden, France, Italy
Merck Sharp & Dohme LLC

Completed

Monotherapy Study in Patients With Type 2 Diabetes Mellitus (0431-021)

Diabetes Mellitus, Type 2
Centre Hospitalier Universitaire de Pointe-a-Pitre

Not yet recruiting

Efficacy of Metformin Versus Sitagliptin on Benign Thyroid Nodules in Type 2 Diabetes (METNODTHYR)

Diabetes Mellitus, Type 2 | Thyroid Nodule (Benign)

France, Guadeloupe, Réunion
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202)

Type 2 Diabetes Mellitus
GlaxoSmithKline

Completed

Prescription Patterns, Resource Utilization & Costs - Add-on Therapy With Anti Dipeptidyl Peptidase-IVs vs Rosiglitazone

Diabetes Mellitus, Type 2

3

Subscribe